Status:
RECRUITING
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Lead Sponsor:
Kochi University
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
PHASE3
Brief Summary
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Detailed Description
gemcitabine plus S-1 versus gemcitabine plus nab-paclitaxel
Eligibility Criteria
Inclusion
- elective pancreatectomy for pancreatic cancer
Exclusion
- a previous cancer surgery a body weight loss of \>10% during the 6 months before surgery the presence of distant metastases seriously impaired function of vital organs because of respiratory, renal, or heart disease.
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2030
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT05268692
Start Date
January 1 2019
End Date
December 31 2030
Last Update
March 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Takehiro Okabayashi
Kochi, Japan, 781-8555